This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AVNS vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
AVNS vs. EW: Which Stock Is the Better Value Option?
DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) second-quarter 2023 results are likely to reflect rising volumes across all channels.
Baxter (BAX) to Post Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) second-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.
Intuitive Surgical (ISRG) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.
Avanos' (AVNS) Latest Buyout to Boost Its RF Product Offering
by Zacks Equity Research
Avanos' (AVNS) latest acquisition is expected to strengthen its foothold with a comprehensive suite of RF offerings.
Masimo (MASI) Down 6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avanos (AVNS) Q1 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
Despite strength in Avanos' (AVNS) Chronic Care segment, its overall first-quarter results reflect soft performances.
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.
Avanos Medical (AVNS) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of -3.57% and 1.54%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
National Vision's (EYE) share price is likely to grow following the company's efforts to expand remote capabilities and investments in doctor recruiting and retention efforts.
Hologic (HOLX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 20.45% and 6.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about Neogen (NEOG) owing to strong performance across its Animal Safety and Food Safety segments.
Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Quest Diagnostics (DGX) base business registers growth in the first quarter of 2023.
Integra's (IART) Q1 Earnings Match Estimates, Margins Contract
by Zacks Equity Research
In CSS, Integra (IART) witnesses a good start to the year with double-digit growth in the CUSA product line and programmable valves as well as strong performance in instrument sales.
Edwards Lifesciences (EW) Q1 Earnings Top Estimates, '23 View Up
by Zacks Equity Research
Edwards Lifesciences (EW) continues to register strong momentum in TMTT, led by the continued adoption of the PASCAL Precision system in Europe.
Align Technology (ALGN) Q1 Earnings Beat, Margins Contract
by Zacks Equity Research
Align Technology (ALGN) delivers better-than-expected revenues and earnings in the first quarter of 2023 but suffers significant foreign currency woes.
Boston Scientific (BSX) Q1 Earnings Beat, 2023 View Raised
by Zacks Equity Research
Reported and organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in the reported quarter.
Thermo Fisher (TMO) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
The year-over-year growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments drove Thermo Fisher's (TMO) Q1 revenues.
LabCorp (LH) Q1 Earnings Miss Estimates, Margins Decline
by Zacks Equity Research
The decline in COVID-19 PCR and antibody testing sales, the severe foreign exchange headwind and inflationary pressure hurt LabCorp's (LH) business performance in Q1.
Here's Why You Should Invest in Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on the increased adoption of its premium RESILIA technologies.
3 Reasons to Retain HealthEquity (HQY) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Adaptive Biotechnologies (ADPT) and Avanos Medical (AVNS) have performed compared to their sector so far this year.
Neogen (NEOG) New Buyouts Aid Growth Amid Rise in Expenses
by Zacks Equity Research
Neogen's (NEOG) performance of the Food Safety business is strong, driven by several long-term secular tailwinds.
Zimmer Biomet (ZBH) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet's (ZBH) continued business recovery.
Masimo's (MASI) New FDA Approval to Improve Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) receipt of the FDA's clearance for the Rad-G with Temperature is expected to support clinicians in almost any care scenario.